7Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
8Lepow ML,Balassanian N,Emmerich J,et al.Interrelationships of viral,mycoplasmal,and bacterial agents in uncomplicated pneumonia.Am Rev Respir Dis,1968,97:533-545.
9Lim WS,Macfarlane JT,Boswell TC,et al.Study of community acquired pneumonia aetiology(SCAPA) in adults admitted to hospital:implications for management guidelines.Thorax,2001,56:296-301.
10Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the management of adults with community-acquired pneumonia.Diagnosis,assessment of severity,antimicrobial therapy,and prevention.Am J Respir Crit Care Med,2001,163:1730-1754.
2Belen Rocio I,Angela Beatriz, Di Giulio, et al. Evaluation of Mycobacterium tuberculosis cross-resistance to isoni- azid,rifampicin and levofloxacin with their respective structural analogs[J]. Journal of Antibiotics, 2014,67 ( 11) : 749-754.
3Vitorino M D S, Rosane Rodrigues M, Letlcia Rita F, et al. Unsuspected tuberculosis in COPD and use of levofloxacin :Diagnostic challenges[J]. Le Infezioni in Medicina Rivista Periodica Di Eziologia Epidemiologia Diagnostica Clinica E Terapia Delle Patologie Infettive,2014,22(4):309-12.
4Kempker RR, Barth AB, Vashakidze S, et al. Cavitary pen- etration of levofloxacin among patients with multidrug-re- sistant tuberculosis[J]. Antimicrob Agents Chemother, 2015, 59(6) :3149-3155.
5Alsuhan A, An G,Peloquin CA. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis[J]. Antimicrob Agents Chemother,2015, 59(7) : 3800-3807.
